Pro­to­cols: The My­lan furor comes in­to play for Cal­i­for­nia drug ini­tia­tive; Ado­cia con­cedes a PhI­II flop

There were times this week where it would have been hard to be­lieve that some­thing oth­er than the EpiPen scan­dal was go­ing on in the in­dus­try. These furors suck up oxy­gen like a for­est fire. And they are in­fi­nite­ly adapt­able. In Cal­i­for­nia, a LA Times colum­nist used the is­sue to high­light the $100 mil­lion phar­ma rep­re­sen­ta­tives are spend­ing to de­feat the Drug Price Re­lief Act, which would re­quire some long-ab­sent price trans­paren­cy. And it would cap prices for drugs used by Me­di-Cal at the (ne­go­ti­at­ed) rate paid by the VA. The al­ter­na­tive, says the colum­nist, is a sys­tem in which the My­lans of the world will con­tin­ue to dom­i­nate. You can bet in­dus­try lob­by­ists are pray­ing that the My­lan storm blows over soon.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER